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(57) ABSTRACT 
Disclosed herein are novel methods for screening for com-
pounds useful in treating telomerase positive cancers. In 
exemplary embodiments, screening methods are based on the 
implementation or manipulation of therapeutic agents that 
up-regulate activity or expression ofMKRN polypeptides or 
polynucleotides encoding the same, respectively. The meth-
ods are useful in identifying agents that can serve as cancer 
therapeutic agents. 
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2 
either alone or before treatment with GA. (B) Concentration 
dependence of GA on hTERT. H1299 cells transfected with 
Flag-hTERT or hTERT-HA were treated for 2 hours with the 
GA concentration indicated. The hTERT polypeptides were CROSS-REFERENCE TO RELATED 
APPLICATIONS 
This application is related to U.S. Provisional application 
Ser. No. 60/78S,414 filed Mar. 23, 2006, and claims priority to 
such application under 3S USC §119. 
5 visualized with anti-Flag or anti-HA antibodies as marked by 
each blot. (C) Down-regulation of endogenous hTERT by 
GA. H1299 cells were treated with 0.1 µM GA for the indi-
cated times, and cell lysates were analyzed by immunopre-
cipitation with anti-hTERT antibody followed by immunob-
lO lotting using same antibody probe. Cells were pretreated with 
10 µM MG132 for 2 hours, either alone or before treatment 
with GA. Molecular weight markers are shown inkilodaltons. 
(D) H1299 cells were treated with 0.1 µM GA for the indi-
BACKGROUND 
Telomeres are essential and functional components of the 
physical ends of eukaryotic chromosomes (Blackbum 1991 ; 
Greider 1996). Telomeres enable cells to distinguish chromo-
some ends from double-strand breaks in the genome. Without 
functional telomeres, the chromosomes are prone to nucle-
olytic degradation leading to cell death through apoptosis and 
may rearrange by genetic recombination or end-to-end fusion 
(Counter et al. 1992; Blasco et al. 1997; Artandi et al. 2002). 
Most normal human somatic cells show a progressive loss of 
telomeric DNA during successive rounds of cell division due 
15 cated times, and cell lysates were analyzed for telomerase 
activity by the TRAP assay. The lane labeled LB corresponds 
to the negative control (lysis buffer only). ITAS represents the 
internal telomerase assay standard. (E) Saos-2 cells trans-
fected with Flag-hTERT or hTERT-HA or empty vector were 
20 untreated or treated with 0.1 µM GA for 16 hours, and cell 
lysates were analyzed for telomerase activity using the TRAP 
to a DNA end replication problem (Lingner et al. 199S). Thus, 
telomere shortening has been proposed as a ticketing mecha-
nism that controls the replicative capacity of cells and cellular 25 
senescence (Harley 1991). Cells with extended replicative 
life spans have mechanisms to counteract loss of telomeric 
DNA. In most human cancer cells, telomere shortening is 
alleviated by telomerase, a ribonucleoprotein enzyme that is 
composed of a catalytic subunit, hTERT, and its template 30 
RNA, hTR (Blackburn 1992; Counter et al. 1992). Telom-
erase activity is detectably expressed in the majority of 
human cancer cells but is repressed in most normal somatic 
cells (Kim et al. 1994). Since introduction ofhTERT gene 
into normal somatic cells extends the life-span of the cells, the 35 
immortalized phenotype of most cancer cells would involve 
activation oftelomerase (Bodnar et al. 1998). 
Telomerase activity correlates with hTERT expression, 
implicating this catalytic subunit as the rate-limiting compo-
nent of the telomerase holoenzyme (Nakamura and Cech 40 
1998). Although telomerase activity is regulated by gene 
expression for hTERT (Wang et al. 1998; Wu et al. 1999; 
Meyerson et al. 1997), several lines of evidence have sug-
gested a post-translational regulation of telomerase activity. 
One possible mechanism for the post-translational modifica- 45 
ti on oftelomerase is the interaction ofhTERTwith accessory 
proteins such as enzymes, chaperones, and polypeptide modi-
fiers (Lee et al. 2004; Liu 1999; Zhou and Lu 2001). Recent 
studies have shown that the molecular chaperone Hsp90 
binds specifically to hTERT to promote the assembly of 50 
active telomerase both in a cell-free system and in intact cells 
(Holt et al. 1999). Moreover, inhibition ofHsp90 function in 
cells blocks assembly of active telomerase. However, the 
underlying mechanism has not been elucidated. 
Identifying cellular mechanisms that control the activity of 55 
telomerases may provide new and helpful targets for estab-
lishing new cancer therapy agents. 
BRIEF DESCRIPTION OF THE DRAWINGS 
assay. 
FIG. 2. hTERT is ubiquitinated prior to proteasome-medi-
ated degradation. (A) H1299 cells were co-transfected with 
Flag-hTERT and HA-ubiquitin. Cells were either untreated 
or treated for 2 hours with 10 µg/ml ALLnN or 0.1 µM GA, or 
a combination of the two as specified above each lane. Immu-
noprecipitation was performed with anti-Flag antibody 
before probing with anti-hTERT or anti-HA antibodies as 
indicated besides each blot. Molecular weight markers are 
shown in kilodaltons. (B) H1299 cells co-transfected with 
Flag-hTERT and HA-ubiquitin were treated for 1 hour with 
the GA concentration indicated in the presence of 10 µM 
MG132. Immunoprecipitation was performed with anti-Flag 
antibody followed by immunoblotting using an anti-HA anti-
body pro be. (C) H1299 cells co-transfected withFlag-hTERT 
and HA-ubiquitin were either untreated or treated for 2 hours 
with 10 µg/ml ALLnN as specified above each lane. Proteins 
were immunoprecipated with anti-Flag antibody followed by 
immunoblotting using an anti-HA antibody probe. 
FIG. 3. MKRNl interacts withhTERT. (A) Analysis of the 
physical interaction between hTERT and MKRNl using the 
yeast two-hybrid assay. Five domains of hTERT were ana-
lyzed for binding to MKRNl. TRFl bait was used as a nega-
tive control. Blue signal on the SG-HWU/X plate indicates 
activation of the reporter gene, Lacz. S, synthetic; G, galac-
tose; H, histidine (-); W, tryptophan (-); U, uracil (-); X, 
X-gal. (B) Schematic diagram of MKRNl domains. Amino 
acid sequences (SEQ ID NOS 3-S, respectively in order of 
appearance) surrounding the RING finger domain in MKRNl 
and mutants used in this study. Cysteines and a histidine in the 
RING finger domain are shown in red. Mutated residue in 
MKRNlH3o7E is shown in blue. (C) H1299 cells co-trans-
fected with hTERT-HA and MKRNl-VS were either 
untreated or treated for 2 hours with 10 µg/ml ALLnN. Anti-
HA immunoprecipitates were analyzed by immunoblotting 
using an anti-VS antibody probe. The left panel shows the 
immunoblot of cell lysates (3% of the precipitated lysates) 
probed with anti-VS antibody. hTERT-HA was visualized 
FIG. 1. hTERT is sensitive to the Hsp90 antagonist 
geldanamycin. (A) Down-regulation of ectopically expressed 
hTERT by GA. H1299 cells transfected with Flag-hTERT or 
Flag-TRFl were treated with 0.1 µM GA for the indicated 
times. Lysates were resolved on 8% SDS-PAGE and analyzed 
by immunoblotting using an anti-Flag antibody probe. Cells 
were pretreated with 10 µM MG132 or E-64 for 2 hours, 
60 with an anti-HA antibody probe. (D) H1299 cells co-trans-
fected with Flag-hTERT and MKRNl-VS were either 
untreated or treated for 2 hours with 10 µM MG132. Anti-
Flag immunoprecipitates were analyzed by immunoblotting 
using an anti-VS antibody probe. The left panel shows the 
65 immunoblot of cell lysates (3% of the precipitated lysates) 
probed with anti-VS antibody. Flag-hTERT was visualized 
with an anti-Flag antibody probe. 
US 7,901,906 B2 
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FIG. 4. MKRNl functions as an E3 ubiquitin-ligase for 
hTERT in vitro and in vivo. (A) HA-tagged hTERT (residues 
946-1132) was incubated MKRNl or mutants in the presence 
ofEl, E2, Hiscubiquitin ( 6xHis tag disclosed as SEQ ID NO: 
7). Samples were resolved by 6% SDS-PAGE and analyzed 5 
by immunoblotting with an anti-HA antibody probe. (B) 
H1299 cells were co-transfected withFlag-hTERT, HA-ubiq-
uitin, MKRNl-VS, and together with either MKRNlH3 o7E_ 
VS or MKRNl ,i.c_ VS as specified. Cells were untreated or 
treated with 10 µM MG132 for 2 hours. Anti-Flag immuno- 10 
precipitates and cell lysates were analyzed by immunoblot-
ting with anti-HA antibody and anti-VS antibody probes, 
respectively. (C) H1299 cells co-transfected with Flag-
hTERT and HA-ubiquitin, and together with or without 
MKRNl-VS as indicated were treated with 10 µM MG132 15 
for the indicated times. Anti-Flag immunoprecipitates and 
cell lysates were analyzed by immunoblotting with anti-HA 
antibody and anti-VS antibody probes, respectively. 
FIG. 5. Overexpression ofMKRNl decreases telomerase 
activity and telomere length. (A) HT1080 cells were stably 20 
transfected with MKRNl-VS or an empty vector. The cells 
were untreated or treated for 2 hours with 10 µMM G 13 2. Cell 
lysates were analyzed by immunoblotting with anti-VS anti-
body probe. (B) Stable HTl 080 cell lines (MKRNl and vec-
tor) were harvested at 4S PD, and telomerase activities were 25 
measured with different amounts of proteins using the TRAP 
assay. The lane labeled LB corresponds to the negative con-
trol (lysis buffer only). ITAS represents the internal telom-
erase assay standard. (C) Cell lysates from stable HTl 080 cell 
lines were analyzed by immunoprecipitation with anti- 30 
hTERT antibody followed by immunoblotting using same 
antibody probe. (D) Representative results ofRT-PCR analy-
sis forthe expression ofMKRNl, hTERT, andhTR in stable 
HTl 080 cell lines. RT-PCR products from each sample were 
normalized to glyceraldehyde-3-phosphate dehydrogenase 35 
(GAPDH) signal. (E) Stable HT1080 cell lines were har-
vested at 4S PD, and genomic DNA was digested with RsaI 
and Hinfl, followed by Southern blotting using a telomere 
repeat probe. 
4 
regulate MKRN-1 activity. A further embodiment of the sub-
ject invention pertains to methods of treating cancers by 
administrating therapeutic agents that up-regulate MKRN-1 
activity. 
In reviewing the detailed disclosure which follows, and the 
specification more generally, it should be borne in mind that 
all patents, patent applications, patent publications, technical 
publications, scientific publications, and other references ref-
erenced herein are hereby incorporated by reference in this 
application in order to more fully describe the state of the art 
to which the present invention pertains. 
Reference to particular buffers, media, reagents, cells, cul-
ture conditions and the like, or to some subclass of same, is 
not intended to be limiting, but should be read to include all 
such related materials that one of ordinary skill in the art 
would recognize as being of interest or value in the particular 
context in which that discussion is presented. For example, it 
is often possible to substitute one buffer system or culture 
medium for another, such that a different but known way is 
used to achieve the same goals as those to which the use of a 
suggested method, material or composition is directed. 
It is important to an understanding of the present invention 
to note that all technical and scientific terms used herein, 
unless defined herein, are intended to have the same meaning 
as commonly understood by one of ordinary skill in the art. 
The techniques employed herein are also those that are known 
to one of ordinary skill in the art, unless stated otherwise. For 
purposes of more clearly facilitating an understanding the 
invention as disclosed and claimed herein, the following defi-
nitions are provided. 
1. Screening Methods 
The invention provides assays for screening test com-
pounds which bind to or modulate the activity of an MKRN 
polypeptide or bind to and inhibit or affect expression of an 
MKRN polynucleotide. A test compound preferably binds to 
an MKRN polypeptide. More preferably, a test compound 
decreases or increases MKRN activity by at least about 10, 
preferably about SO, more preferably about 7S, 90, or 100% 
relative to the absence of the test compound. 
40 1.1. Test Compounds 
DETAILED DESCRIPTION 
The subject invention is based on the inventors discovery 
that ubiquitination of telomerase is induced by a novel protein 
MKRN-1. The up-regulation of MKRN-1 induces ubiquiti-
nation of one or more components of telomerase which 
causes a degradation in telomerase activity. The degradation 
of telomerase activity ultimately leads to degradation of 
telomeres in the cells, and eventually cell death. Cells of many 
types of cancers are known to be telomerase positive. Thus, 
the inventors discovery enables the targeting ofMKRN-1 to 
serve as a basis for novel cancer therapies. 
Not being bound by any particular theory, the inventors 
found that disruption of Hsp90 function by geldanamycin 
(GA) promotes ubiquitination and proteasome-mediated 
degradation of hTERT. Furthermore, they have identified a 
novel hTERT binding protein MKRNl that functions as an E3 
ligase and mediates ubiquitination ofhTERT in vivo and in 
vitro. Overexpression of MKRNl in telomerase-positive 
cells decreases telomerase activity and telomere length. 
These observations indicate that MKRNl, a post-transla-
tional modifier ofhTERT, exerts a negative role in telomere 
length homeostasis. 
A particular embodiment of the subject invention pertains 
to methods of screening for test compounds that modulate the 
activity of MKRN-1 polypeptides. Another embodiment of 
the subject invention pertains to therapeutic agents that up-
Test compounds relate to agents that potentially have thera-
peutic activity, i.e., bind to or modulate the activity of an 
MKRN polypeptide or bind to or affect expression of an 
MKRN polynucleotide. Test compounds can be pharmaco-
45 logic agents already known in the art or can be compounds 
previously unknown to have any pharmacological activity. 
The compounds can be naturally occurring or designed in the 
laboratory. They can be isolated from microorganisms, ani-
mals, or plants, and can be produced recombinantly, or syn-
50 thesized by chemical methods known in the art. If desired, test 
compounds can be obtained using any of the numerous com-
binatorial library methods known in the art, including but not 
limited to, biological libraries, spatially addressable parallel 
solid phase or solution phase libraries, synthetic library meth-
55 ods requiring deconvolution, the "one-bead one-compound" 
library method, and synthetic library methods using affinity 
chromatography selection. The biological library approach is 
limited to polypeptide libraries, while the other four 
approaches are applicable to polypeptide, non-peptide oligo-
60 mer, or small molecule libraries of compounds. See Lam, 
Anticancer Drug Des. 12, 14S, 1997. 
Methods for the synthesis of molecular libraries are well 
known in the art (see, for example, DeWitt et al., Proc. Natl. 
Acad. Sci. U.S.A. 90, 6909, 1993; Erb eta!. Proc. NatL.Acad. 
65 Sci. U.S.A. 91, 11422, 1994; Zuckermann et al., J. Med. 
Chem. 37, 2678, 1994; Cho et al., Science 261, 1303, 1993; 
Carell et al., Angew. Chem. Int. Ed. Engl. 33, 20S9, 1994; 
US 7,901,906 B2 
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Carell et al.,Angew. Chem. Int. Ed. Engl. 33, 2061; Gallop et 
al., J. Med. Chem. 37, 1233, 1994). 
1.2. High Throughput Screening 
Test compounds can be screened for the ability to bind to 
and up-regulate MKRN polypeptides orpolynucleotides or to 5 
affect MKRN activity or MKRN gene expression using high 
throughput screening. Using high throughput screening, 
many discrete compounds can be tested in parallel so that 
large numbers of test compounds can be quickly screened. 
The most widely established techniques utilize 96-well 10 
microtiter plates. The wells of the microtiter plates typically 
require assay volumes that range from 50 to 500 µ!.In addi-
tion to the plates, many instruments, materials, pipettors, 
robotics, plate washers, and plate readers are commercially 
15 
available to fit the 96-well format. Alternatively, "free format 
assays," or assays that have no physical barrier between 
samples, can be used. 
1.3. Binding Assays 
For binding assays, the test compound is preferably, but not 20 
necessarily, a small molecule which binds to and occupies, for 
example, the active site of the MKRN polypeptide, such that 
normal biological activity is prevented. Examples of such 
small molecules include, but are not limited to, small peptides 
or peptide-like molecules, or non-peptide small molecules 25 
such as organics identified by high throughput screens (e.g., 
chemical library screening). 
In binding assays, either the test compound or the MKRN 
polypeptide can comprise a detectable label, such as a fluo-
rescent, radioisotopic, chemiluminescent, or enzymatic label, 30 
such as horseradish peroxidase, alkaline phosphatase, or 
luciferase. Detection of a test compound which is bound to 
the MKRN polypeptide can then be accomplished, for 
example, by direct counting ofradioemmission, by scintilla-
35 
ti on counting, or by determining conversion of an appropriate 
substrate to a detectable product. 
6 
and Brent W094/10300), to identify other proteins which 
bind to or interact with the MKRN polypeptide and modulate 
its activity. 
In many screening embodiments, it may be desirable to 
immobilize either the MKRN polypeptide (or polynucle-
otide) or the test compound to facilitate separation of bound 
from unbound forms of one or both of the interactants, as well 
as to accommodate automation of the assay. Thus, either the 
MKRN polypeptide ( orpolynucleotide) or the test compound 
can be bound to a solid support. Suitable solid supports 
include, but are not limited to, glass or plastic slides, tissue 
culture plates, microtiter wells, tubes, silicon chips, or par-
ticles such as beads (including, but not limited to, latex, 
polystyrene, or glass beads). Any method known in the art can 
be used to attach the MKRN polypeptide (or polynucleotide) 
or test compound to a solid support, including use of covalent 
and non-covalent linkages, passive absorption, or pairs of 
binding moieties attached respectively to the polypeptide (or 
polynucleotide) or test compound and the solid support. Test 
compounds are preferably bound to the solid support in an 
array, so that the location of individual test compounds can be 
tracked. Binding of a test compound to a MKRN polypeptide 
(or polynucleotide) can be accomplished in any vessel suit-
able for containing the reactants. Examples of such vessels 
include microtiter plates, test tubes, and microcentrifuge 
tubes. 
In a specific embodiment, the MKRN polypeptide may be 
a fusion protein comprising a domain that allows the MKRN 
polypeptide to be bound to a solid support. For example, 
glutathione S-transferase fusion proteins can be adsorbed 
onto glutathione sepharose beads (Sigma Chemical, St. 
Louis, Mo.) or glutathione derivatized microtiter plates, 
which are then combined with the test compound or the test 
compound and the nonadsorbed MKRN polypeptide; the 
mixture is then incubated under conditions conducive to com-
plex formation (e.g., at physiological conditions for salt and 
pH). Following incubation, the beads ormicrotiterplate wells 
are washed to remove any unbound components. Binding of 
the interactants can be determined either directly or indi-
rectly, as described above. Alternatively, the complexes can 
be dissociated from the solid support before binding is deter-
mined. 
Other techniques for immobilizing proteins or polynucle-
otides on a solid support also can be used in the screening 
assays of the invention. For example, either a MKRN 
polypeptide (or polynucleotide) or a test compound can be 
immobilized utilizing conjugation of biotin and streptavidin. 
BiotinylatedMKRN polypeptides ( orpolynucleotides) or test 
compounds can be prepared from biotinNHS(Nhydroxysuc-
Those skilled in the art equipped with teachings herein will 
appreciate that there are multiple conventional methods of 
detecting binding of a test compound. For example, binding 40 
of a test compound to a MKRN polypeptide can be deter-
mined without labeling either of the interactants. A micro-
physiometer can be used to detect binding of a test compound 
with an MKRN polypeptide. A microphysiometer (e.g., 
CYTOSENSOR™) is an analytical instrument that measures 45 
the rate at which a cell acidifies its environment using a 
light-addressable potentiometric sensor (LAPS). Changes in 
this acidification rate can be used as an indicator of the inter-
action between a test compound and an MKRN polypeptide 
(McConnell et al., Science 257, 19061912, 1992). 
In another alternative example, determining the ability of a 
test compound to bind to an MKRN polypeptide can be 
accomplished using a technology such as real-time Bimo-
lecular Interaction Analysis (BIA) (Sjolander & Urbaniczky, 
Anal Chem. 63, 23382345, 1991, and Szabo et al., Curr. Opin. 55 
Struct. Biol. 5, 699705, 1995). BIA is a technology for study-
ing biospecific interactions in real time, without labeling any 
50 cinimide) using techniques well known in the art (e.g., bioti-
nylation kit, Pierce Chemicals, Rockford, Ill.) and immobi-
lized in the wells of streptavidin-coated 96 well plates (Pierce 
Chemical). Alternatively, antibodies which specifically bind 
of the interactants (e.g., BIAcore.™). Changes in the optical 
phenomenon surface plasmon resonance (SPR) can be used 
as an indication of real-time reactions between biological 60 
molecules. 
In yet another aspect of the invention, an MKRN polypep-
tide can be used as a "bait protein" in a two-hybrid assay or 
three-hybrid assay (see, e.g., U.S. Pat. No. 5,283,317; Zervos 
et al., Cell 72, 223232, 1993; Madura et al., J. Biol. Chem. 65 
268, 1204612054, 1993; Bartel et al., BioTechniques 14, 
920924, 1993; Iwabuchi et al., Oncogene 8, 16931696, 1993; 
to a MKRN polypeptide, polynucleotide, or a test compound, 
but which do not interfere with a desired binding site, such as 
the active site of the MKRN polypeptide, can be derivatized to 
the wells of the plate. Unbound target or protein can be 
trapped in the wells by antibody conjugation. 
Methods for detecting such complexes, in addition to those 
described above for the GST-immobilized complexes, 
include immunodetection of complexes using antibodies 
which specifically bind to the MKRN polypeptide or test 
compound, enzyme-linked assays which rely on detecting an 
activity of the MKRN polypeptide, and SDS gel electro-
phoresis under non-reducing conditions. 
Screening for test compounds which bind to a MKRN 
polypeptide or polynucleotide also can be carried out in an 
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intact cell. Any cell which comprises a MKRN polypeptide or 
polynucleotide can be used in a cell-based assay system. A 
MKRN polynucleotide can be naturally occurring in the cell 
or can be introduced using techniques such as those described 
above. Binding of the test compound to a MKRN polypeptide 
or polynucleotide is determined as described above. 
1.4. EnzymeAssays 
Test compounds can be tested for the ability to increase or 
decrease the MKRN activity of a MKRN polypeptide. 
MKRN activity can be measured, for example, by adapting 10 
techniques such as that described in U.S. Pat. No. 4,529,693 
(see Example 2). Enzyme assays can be carried out after 
contacting either a purified MKRN polypeptide, a cell mem-
brane preparation, or an intact cell with a test compound. A 
test compound which decreases ligase activity of a MKRN 15 
polypeptide by at least about 10, preferably about 50, more 
preferably about 75, 90, or 100% is identified as a potential 
therapeutic agent for decreasing MKRN activity. A test com-
pound which increases ligase MKRN polypeptide by at least 
about 10, preferably about 50, more preferably about 75, 90, 20 
or 100% is identified as a potential therapeutic agent for 
increasing MKRN activity. 
1.5. Gene Expression 
In another embodiment, test compounds which increase or 
decrease MKRN gene expression are identified. An MKRN 25 
polynucleotide is contacted with a test compound, and the 
expression of an RNA or polypeptide product of the MKRN 
polynucleotide is determined. The level of expression of 
appropriate mRNA or polypeptide in the presence of the test 
compound is compared to the level of expression of mRNA or 30 
polypeptide in the absence of the test compound. The test 
compound can then be identified as a modulator of expression 
based on this comparison. For example, when expression of 
mRNA or polypeptide is greater in the presence of the test 
compound than in its absence, the test compound is identified 35 
as a stimulator or enhancer of the mRNA or polypeptide 
expression. Alternatively, when expression of the mRNA or 
polypeptide is less in the presence of the test compound than 
8 
invention can comprise, for example, therapeutic agents iden-
tified by a screening method embodiment described herein, 
which are identified by their ability to bind to or affect activity 
of MKRN polypeptides, or bind to and/or affect expression 
MKRN polynucleotides. The compositions can be adminis-
tered alone or in combination with at least one other agent, 
such as stabilizing compound, which can be administered in 
any sterile, biocompatible pharmaceutical carrier, including, 
but not limited to, saline, buffered saline, dextrose, and water. 
The compositions can be administered to a patient alone, or in 
combination with other agents, drugs or hormones. 
In addition to the active ingredients, these pharmaceutical 
compositions can contain suitable pharmaceutically accept-
able carriers comprising excipients and auxiliaries which 
facilitate processing of the active compounds into prepara-
tions which can be used pharmaceutically. Pharmaceutical 
compositions of the invention can be administered by any 
number of routes including, but not limited to, oral, intrave-
nous, intramuscular, intra-arterial, intramedullary, intrathe-
cal, intraventricular, transdermal, subcutaneous, intraperito-
neal, intranasal, parenteral, topical, sublingual, or rectal 
means. Pharmaceutical compositions for oral administration 
can be formulated using pharmaceutically acceptable carriers 
well known in the art in dosages suitable for oral administra-
tion. Such carriers enable the pharmaceutical compositions to 
be formulated as tablets, pills, dragees, capsules, liquids, gels, 
syrups, slurries, suspensions, and the like, for ingestion by the 
patient. 
Further details on techniques for formulation and admin-
istration can be found in the latest edition ofREMINGTON'S 
PHARMACEUTICAL SCIENCES (Maack Publishing Co., 
Easton, Pa., which is incorporated herein by reference). After 
pharmaceutical compositions have been prepared, they can 
be placed in an appropriate container and labeled for treat-
ment of an indicated condition. Such labeling would include 
amount, frequency, and method of administration. 
This invention further pertains to the use of novel agents 
identified by the screening assays described above. Accord-
ingly, it is within the scope of this invention to use a thera-in its absence, the test compound is identified as an inhibitor 
of the mRNA or polypeptide expression. 40 peutic agent identified as described herein in an appropriate 
animal model. For example, an agent identified as described 
herein (for example, but not limited to., a modulating agent, 
an antisense nucleic acid molecule, a specific antibody, 
The level of MKRN mRNA or polypeptide expression in 
the cells can be determined by methods well known in the art 
for detecting mRNA or polypeptide. Either qualitative or 
quantitative methods can be used. The presence of polypep-
tide products of an MKRN polynucleotide can be determined, 45 
for example, using a variety of techniques known in the art, 
including immunochemical methods such as radioimmu-
noassay, Western blotting, and immunohistochemistry. Alter-
natively, polypeptide synthesis can be determined in vivo, in 
ribozyme, or a MKRN polypeptide binding molecule) can be 
used in an animal model to determine the efficacy, toxicity, or 
side effects of treatment with such an agent. Furthermore, this 
invention pertains to uses of novel agents identified by the 
above described screening assays for treatments as described 
herein. 
a cell culture, or in an in vitro translation system by detecting 50 
incorporation oflabeled amino acids into a MKRN polypep-
tide. 
Those skilled in the art will appreciate that numerous deliv-
ery mechanisms are available for delivering a therapeutic 
agent to an area of need. By way of example, the agent may be 
delivered using a liposome as the delivery vehicle. Preferably, 
the liposome is stable in the animal into which it has been 
Such screening can be carried out either in a cell-free assay 
system or in an intact cell. Any cell which expresses a MKRN 
polynucleotide can be used in a cell-based assay system. The 
MKRN polynucleotide can be naturally occurring in the cell 
or can be introduced using techniques such as those described 
above. Either a primary culture or an established cell line, 
such as CHO or human embryonic kidney 293 cells, can be 
used. 
2. Pharmaceutical Compositions 
The invention also pertains to pharmaceutical composi-
tions comprising one or more therapeutic agents that are 
identified by screening methods that utilize MKRN polypep-
tides and/or polynucleotides. Therapeutic agent(s) can be 
administered to a patient to achieve a therapeutic effect, i.e. 
useful cancer therapy. Pharmaceutical compositions of the 
55 administered for at least about 30 minutes, more preferably 
for at least about 1 hour, and even more preferably for at least 
about 24 hours. A liposome comprises a lipid composition 
that is capable of targeting a reagent, particularly a polynucle-
60 
otide, to a particular site in an animal, such as a human. 
A liposome useful in the present invention comprises a 
lipid composition that is capable of fusing with the plasma 
membrane of the targeted cell to deliver its contents to the 
cell. Preferably, the transfection efficiency of a liposome is 
about 0.5 µg of DNA per 16 nmole ofliposome delivered to 
65 about 106 cells, more preferably about 1.0 µg of DNA per 16 
nmole ofliposome delivered to about 106 cells, and even more 
preferably about 2.0 µg of DNA per 16 nmol of liposome 
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delivered to about 106 cells. Preferably, a liposome is between 
about 100 and 500 nm, more preferably between about 150 
and 450 nm, and even more preferably between about 200 and 
400 nm in diameter. 
Suitable liposomes for use in the present invention include 
those liposomes standardly used in, for example, gene deliv-
ery methods known to those of skill in the art. More preferred 
liposomes include liposomes having a polycationic lipid 
composition and/or liposomes having a cholesterol backbone 
conjugated to polyethylene glycol. Optionally, a liposome 
comprises a compound capable of targeting the liposome to a 
particular cell type, such as a cell-specific ligand exposed on 
the outer surface of the liposome. 
Complexing a liposome with a reagent such as an antisense 
oligonucleotide or ribozyme can be achieved using methods 
which are standard in the art (see, for example, U.S. Pat. No. 
5,705,151). Preferably, from about 0.1 µg to about 10 µg of 
polynucleotide is combined with about 8 nmol ofliposomes, 
more preferably from about 0.5 µg to about 5 µg of polynucle-
otides are combined with about 8 nmol liposomes, and even 
more preferably about 1.0 µg of polynucleotides is combined 
with about 8 nmol liposomes. 
In another embodiment, antibodies can be delivered to 
specific tissues in vivo using receptor-mediated targeted 
delivery. Receptor-mediated DNA delivery techniques are 
taught in, for example, Findeis et al. Trends in Biotechnol. 11, 
202-05 (1993); Chiou et al., GENE THERAPEUTICS: 
METHODS AND APPLICATIONS OF DIRECT GENE 
TRANSFER (J. A. Wolff, ed.) (1994); Wu & Wu, J. Biol. 
Chem. 263, 621-24 (1988); Wu et al., J. Biol. Chem. 269, 
542-46 (1994); Zenke et al., Proc. Natl. Acad. Sci. U.S.A. 87, 
3655-59 (1990); Wu et al., J. Biol. Chem. 266, 338-42 (1991). 
2.1 Determination of a Therapeutically Effective Dose 
10 
for proteins or their inhibitors. Similarly, delivery of poly-
nucleotides or polypeptides will be specific to particular cells, 
conditions, locations, etc. 
Preferably, a therapeutic agent reduces expression of an 
MKRN gene or the activity of an MKRN polypeptide by at 
least about 10, preferably about 50, more preferably about 7 5, 
90, or 100% relative to the absence of the reagent. The effec-
tiveness of the mechanism chosen to decrease the level of 
expression of an MKRN gene or the activity of an MKRN 
10 polypeptide can be assessed using methods well known in the 
art, such as hybridization of nucleotide probes to MKRN-
specific mRNA, quantitative RT-PCR, immunologic detec-
tion of an MKRN polypeptide, or measurement of MKRN 
15 
activity. 
In any of the embodiments described above, any of the 
pharmaceutical compositions of the invention can be admin-
istered in combination with other appropriate therapeutic 
agents. Selection of the appropriate agents for use in combi-
20 nation therapy can be made by one of ordinary skill in the art, 
according to conventional pharmaceutical principles. The 
combination of therapeutic agents can act synergistically to 
effect the treatment or prevention of the various disorders 
described above. Using this approach, one may be able to 
25 achieve therapeutic efficacy with lower dosages of each 
agent, thus reducing the potential for adverse side effects. 
Any of the therapeutic methods described above can be 
applied to any subject in need of such therapy. 
3. Polypeptides 
30 MKRN polypeptides according to the invention comprise 
at least 12, 15,25, 50, 75, 100, 125, 150, 175,200,225,250 
or 265 contiguous amino acids selected from the amino acid 
sequence shown in SEQ ID NO: 2, or a biologically active 
35 
variant thereof, as defined below. A MKRN polypeptide of 
the invention therefore can be a portion of an MKRN protein, 
a full-length MKRN protein, or a fusion protein comprising 
all or a portion of MKRN protein. 
The determination of a therapeutically effective dose of 
therapeutic agents identified by a screening method herein is 
well within the capability of those skilled in the art. A thera-
peutically effective dose refers to that amount of active ingre-
dient which attenuates or eliminates TB infection contrasted 40 
3.1 Biologically Active Variants 
MKRN polypeptide variants which are biologically active, 
to TB infection or attenuation that occurs in the absence of the 
therapeutically effective dose. 
Therapeutic efficacy and toxicity, e.g., ED50 (the dose 
therapeutically effective in 50% of the population) and LD50 
(the dose lethal to 50% of the population), can be determined 
by standard pharmaceutical procedures in cell cultures or 
experimental animals. The dose ratio of toxic to therapeutic 
effects is the therapeutic index, and it can be expressed as the 
ratio, LD50/ED50 . 
The exact dosage will be determined by the practitioner, in 
light of factors related to the subject that requires treatment. 
Dosage and administration are adjusted to provide sufficient 
levels of the active ingredient or to maintain the desired effect. 
Factors which can be taken into account include the severity 
i.e., confer an ability to initiate degradation ofhTERT, also 
are considered MKRN polypeptides for purposes of this 
application. Preferably, naturally or non-naturally occurring 
MKRN polypeptide variants have amino acid sequences 
45 which are at least about 55, 60, 65, or 70, preferably about 75, 
80, 85, 90, 96, 96, or 98% identical to the amino acid sequence 
shown in SEQ ID NO: 2 or a fragment thereof. Percent iden-
tity between a putative MKRN polypeptide variant and an 
amino acid sequence of SEQ ID NO: 2 is determined using 
50 the Blast2 alignment program (Blosum62, Expect 10, stan-
dard genetic codes). 
Variations in percent identity can be due, for example, to 
amino acid substitutions, insertions, or deletions. Amino acid 
substitutions are defined as one for one amino acid replace-
55 ments. They are conservative in nature when the substituted 
amino acid has similar structural and/or chemical properties. 
Examples of conservative replacements are substitution of a 
leucine with an isoleucine or valine, an aspartate with a 
of the disease state, general health of the subject, age, weight, 
and gender of the subject, diet, time and frequency of admin-
istration, drug combination(s), reaction sensitivities, and tol-
erance/response to therapy. Long-acting pharmaceutical 
compositions can be administered every 3 to 4 days, every 
week, or once every two weeks depending on the half-life and 60 
clearance rate of the particular formulation. 
glutamate, or a threonine with a serine. 
Amino acid insertions or deletions are changes to or within 
an amino acid sequence. They typically fall in the range of 
about 1 to 5 amino acids. Guidance in determining which 
amino acid residues can be substituted, inserted, or deleted 
without abolishing biological or immunological activity of an 
Normal dosage amounts can vary from 0.1 to 100,000 
micrograms, up to a total dose of about 1 g, depending upon 
the route of administration. Guidance as to particular dosages 
and methods of delivery is provided in the literature and 
generally available to practitioners in the art. Those skilled in 
the art will employ different formulations for nucleotides than 
65 MKRN polypeptide can be found using computer programs 
well known in the art, such as DNASTAR software. Whether 
an amino acid change results in a biologically active MKRN 
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polypeptide can readily be determined by assaying for 
MKRN activity, as described for example, in the specific 
Examples, below. 
3.2 Fusion Proteins 
12 
polypeptides is at least 80% pure; preferably, the preparations 
are 90%, 95%, or 99% pure. Purity of the preparations can be 
assessed by any means known in the art, such as SDS-poly-
acrylamide gel electrophoresis. 
4. Polynucleotides 
An MKRN polynucleotide can be single- or double-
stranded and comprises a coding sequence or the complement 
of a coding sequence for an MKRN polypeptide. A coding 
sequence for MKRN polypeptide of SEQ ID NO: 2 is shown 
inSEQIDNO: 1. 
Degenerate nucleotide sequences encoding MKRN 
polypeptides, as well as homologous nucleotide sequences 
which are at least about 50, 55, 60, 65, 60, preferably about 
7 5, 90, 96, or 98% identical to the nucleotide sequence shown 
In some embodiments of the invention, it is useful to create 5 
fusion proteins. By way of example, fusion proteins are useful 
for generating antibodies against MKRN polypeptide amino 
acid sequences and for use in various assay systems. For 
example, fusion proteins can be used to identify proteins 
which interact with portions of an MKRN polypeptide. Pro- 10 
tein affinity chromatography or library-based assays for pro-
tein-protein interactions, such as the yeast two-hybrid or 
phage display systems, can be used for this purpose. Such 
methods are well known in the art and also can be used as drug 
screens. 15 in SEQ ID NO: 1 also are MKRN polynucleotides. Percent 
sequence identity between the sequences of two polynucle-
otides is determined using computer programs such as 
ALIGN which employ the FAS TA algorithm, using an affine 
gap search with a gap open penalty of -12 and a gap extension 
A MKRN polypeptide fusion protein comprises two 
polypeptide segments fused together by means of a peptide 
bond. For example, the first polypeptide segment can com-
prise at least 12, 15, 25, 50, 75, 100, 125, 150, 175, 200, 225, 
or 250 contiguous amino acids of SEQ ID NO: 2 or of a 
biologically active variant, such as those described above. 
The first polypeptide segment also can comprise full-length 
MKRN protein. 
20 penalty of-2. Complementary DNA ( cDNA) molecules, spe-
cies homo logs, and variants ofMKRN polynucleotides which 
encode biologically active MKRN polypeptides also are 
MKRN polynucleotides. 
4.1 Identification of Polynucleotide Variants and Homologs 
Variants and homologs of the MKRN polynucleotides 
described above also are MKRN polynucleotides. Typically, 
homologous MKRN polynucleotide sequences can be iden-
tified by hybridization of candidate polynucleotides to known 
MKRN polynucleotides under stringent conditions, as is 
30 known in the art. For example, using the following wash 
conditions: 2xSSC (0.3 M NaCl, 0.03 M sodium citrate, pH 
7.0), 0.1 % SDS, room temperature twice, 30 minutes each; 
then 2xSSC, 0.1 % SDS, 50° C. once, 30 minutes; then 
2xSSC, room temperature twice, 10 minutes each homolo-
The second polypeptide segment can be a full-length pro-
tein or a protein fragment. Proteins commonly used in fusion 25 
protein construction include galactosidase, glucuronidase, 
green fluorescent protein (GFP), autofluorescent proteins, 
including blue fluorescent protein (BFP), glutathione-S-
transferase (GST), luciferase, horseradish peroxidase (HRP), 
and chloramphenicol acetyltransferase (CAT). Additionally, 
epitope tags are used in fusion protein constructions, includ-
ing histidine (His) tags, FLAG tags, influenza hemagglutinin 
(HA) tags, Myc tags, VSV-G tags, and thioredoxin (Trx) tags. 
Other fusion constructions can include maltose binding pro-
tein (MBP), S-tag, Lex a DNA binding domain (DBD) 
fusions, GAL4 DNA binding domain fusions, and herpes 
simplex virus (HSY) BPI 6 protein fusions. A fusion protein 
also can be engineered to contain a cleavage site located 
between the MKRN polypeptide-encoding sequence and the 
heterologous protein sequence, so that the MKRN polypep-
tide can be cleaved and purified away from the heterologous 
moiety. 
35 gous sequences can be identified which contain at most about 
25-30% basepair mismatches. More preferably, homologous 
nucleic acid strands contain 15-25% basepair mismatches, 
even more preferably 5-15% basepair mismatches. 
Species homologs of the MKRN polynucleotides dis-
40 closed herein also can be identified by making suitable probes 
or primers and screening cDNA expression libraries. It is well 
known that the Tm of a double-stranded DNA decreases by 
1-1.5° C. with every 1 % decrease in homology (Bonner et al., 
J. Mo!. Biol. 81, 123 (1973 ). Variants of MKRN polynucle-
Many kits for constructing fusion proteins are available 
from companies such as Promega Corporation (Madison, 
Wis.), Stratagene (La Jolla, Calif.), CLONTECH (Mountain 
View, Calif.), Santa Cruz Biotechnology (Santa Cruz, Calif.), 
MBL International Corporation (MIC; Watertown, Mass.), 
and Quantum Biotechnologies (Montreal, Canada; 1-888-
DNA-KITS). 
3.3 Obtaining Polypeptides 
MKRN polypeptides can be obtained, for example, by 
purification of polypeptides from cells, expressing MKRN 
polynucleotide(s) and other appropriate methods as will be 
appreciated by those skilled in the art in view of the teachings 
herein. 
3.4 Protein Purification 
MKRN polypeptides can be purified from any cell which 
expresses the enzyme, including host cells which have been 
transfected with MKRN enzyme expression constructs. A 
purified MKRN enzyme polypeptide is separated from other 
compounds which normally associate with the MKRN 
enzyme polypeptide in the cell, such as certain proteins, car-
bohydrates, or lipids, using methods well-known in the art. 
Such methods include, but are not limited to, size exclusion 
chromatography, ammonium sulfate fractionation, ion 
exchange chromatography, affinity chromatography, and pre-
parative gel electrophoresis. A preparation of purified MKRN 
45 otides or polynucleotides of other species can therefore be 
identified by hybridizing a putative homologous MKRN 
polynucleotide with a polynucleotide having a nucleotide 
sequence of SEQ ID NO: 1 or the complement thereof to form 
a test hybrid. The melting temperature of the test hybrid is 
50 compared with the melting temperature of a hybrid compris-
ing polynucleotides having perfectly complementary nucle-
otide sequences, and the number or percent of basepair mis-
matches within the test hybrid is calculated. 
Nucleotide sequences which hybridize to MKRN poly-
55 nucleotides or their complements following stringent hybrid-
ization and/or wash conditions also are MKRN polynucle-
otides. Stringent wash conditions are well known and 
understood in the art and are disclosed, for example, in Sam-
brook et al., MOLECULAR CLONING: A LABORATORY 
60 MANUAL, rd ed., 1989, at pages 9.50-9.51. 
Typically, for stringent hybridization conditions a combi-
nation of temperature and salt concentration should be chosen 
that is approximately 12-20° C. below the calculated Tm of the 
hybrid under study. The Tm of a hybrid between an MKRN 
65 polynucleotide having a nucleotide sequence shown in SEQ 
ID NO: 1 or the complement thereof and a polynucleotide 
sequence which is at least about 50, preferably about 75, 90, 
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96, or 98% identical to one of those nucleotide sequences can 
be calculated, for example, using the equation of Bolton and 
McCarthy, Proc. Natl. Acad. Sci. U.S.A. 48, 1390 (1962): 
Tm ~81.5° C.-16.6(log 10[Na•])+0.41(% G+C)-0.63(% 
formamide)-600/1), 
where 1 =the length of the hybrid in basepairs. 
Stringent wash conditions include, for example, 4xSSC at 
65° C., or 50% formamide, 4xSSC at 42° C., or 0.5xSSC, 
0.1 % SDS at 65° C. Highly stringent wash conditions include, 
for example, 0.2xSSC at 65° C. 
4.2 Preparation of Polynucleotides 
A naturally occurring MKRN polynucleotide can be iso-
lated free of other cellular components such as membrane 
components, proteins, and lipids. Polynucleotides can be 
made by a cell and isolated using standard nucleic acid puri-
fication techniques, or synthesized using an amplification 
technique, such as the polymerase chain reaction (PCR), or 
14 
The control elements or regulatory sequences are those 
nontranslated regions of the vector enhancers, promoters, 5' 
and 3' untranslated regions which interact with host cellular 
proteins to carry out transcription and translation. Such ele-
ments can vary in their strength and specificity. Depending on 
the vector system and host utilized, any number of suitable 
transcription and translation elements, including constitutive 
and inducible promoters, can be used. For example, when 
cloning in bacterial systems, inducible promoters such as the 
10 hybrid lacZ promoter of the BLUESCRIPT phagemid (Strat-
agene, LaJolla, Calif.) or pSPORTl plasmid (Life Technolo-
gies) and the like can be used. The baculovirus polyhedrin 
promoter can be used in insect cells. Promoters or enhancers 
derived from the genomes of plant cells (e.g., heat shock, 
15 RUBISCO, and storage protein genes) or from plant viruses 
(e.g., viral promoters or leader sequences) can be cloned into 
the vector. In mammalian cell systems, promoters from mam-
malian genes or from mammalian viruses are preferable. If it 
is necessary to generate a cell line that contains multiple 
20 copies of a nucleotide sequence encoding an MKRN 
polypeptide, vectors based on SV 40 or EBY can be used with 
an appropriate selectable marker. 
by using an automatic synthesizer. Methods for isolating 
polynucleotides are routine and are known in the art. Any 
such technique for obtaining a polynucleotide can be used to 
obtain isolated MKRN polynucleotides. For example, restric-
tion enzymes and probes can be used to isolate polynucle-
otide fragments which comprises MKRN nucleotide 25 
sequences. Isolated polynucleotides are in preparations 
which are free or at least 70, 80, or 90% free of other mol-
ecules. 
5. Host Cells 
According to certain embodiments of the subject inven-
tion, an MKRN polynucleotide will need to be inserted into a 
host cell, for expression, processing and/or screening. A host 
cell strain can be chosen for its ability to modulate the expres-
sion of the inserted sequences or to process the expressed 
MKRN polypeptide in the desired fashion. Such modifica-MKRN DNA molecules can be made with standard 
molecular biology techniques, using MKRN mRNA as a 
template. MKRN DNA molecules can thereafter be repli-
cated using molecular biology techniques known in the art 
and disclosed in manuals such as Sambrook et al. (1989). An 
amplification technique, such as PCR, can be used to obtain 
additional copies of polynucleotides of the invention. The 
inventors have successfully demonstrated this approach. 
Alternatively, synthetic chemistry techniques can be used 
to synthesizes MKRN polynucleotides. The degeneracy of 
the genetic code allows alternate nucleotide sequences to be 
synthesized which will encode a MKRN polypeptide having, 
for example, an amino acid sequence shown in SEQ ID NO: 
2 or a biologically active variant thereof. 
4.3 Expression of Polynucleotides 
To express a MKRN polynucleotide, the polynucleotide 
can be inserted into an expression vector which contains the 
necessary elements for the transcription and translation of the 
inserted coding sequence. Methods which are well known to 
those skilled in the art can be used to construct expression 
vectors containing sequences encoding MKRN polypeptides 
and appropriate transcriptional and translational control ele-
ments. These methods include in vitro recombinant DNA 
techniques, synthetic techniques, and in vivo genetic recom-
bination. Such techniques are described, for example, in Sam-
brook et al. (1989) and in Ausubel et al., CURRENT PRO-
TOCOLS IN MOLECULAR BIOLOGY, John Wiley & 
Sons, New York, N.Y., 1989. 
A variety of expression vector/host systems can be utilized 
30 tions of the polypeptide include, but are not limited to, acety-
lation, carboxylation, glycosylation, phosphorylation, lipida-
tion, and acylation. Posttranslational processing which 
cleaves a "prepro" form of the polypeptide also can be used to 
facilitate correct insertion, folding and/or function. Different 
35 host cells which have specific cellular machinery and char-
acteristic mechanisms for post-translational activities (e.g., 
CHO, HeLa, MDCK, HEK293, and W138), are available 
from the American Type Culture Collection (ATCC; 10801 
University Boulevard, Manassas, Va. 20110-2209) and can be 
40 chosen to ensure the correct modification and processing of 
the foreign protein. 
Stable expression is preferred for long-term, high yield 
production of recombinant proteins. For example, cell lines 
which stably express MKRN polypeptides can be trans-
45 formed using expression vectors which can contain viral ori-
gins of replication and/or endogenous expression elements 
and a selectable marker gene on the same or on a separate 
vector. Following the introduction of the vector, cells can be 
allowed to grow for 12 days in an enriched medium before 
50 they are switched to a selective medium. The purpose of the 
selectable marker is to confer resistance to selection, and its 
presence allows growth and recovery of cells which success-
fully express the introduced MKRN sequences. Resistant 
clones of stably transformed cells can be proliferated using 
55 tissue culture techniques appropriate to the cell type. See, for 
example, ANIMAL CELL CULTURE, R. I. Freshney, ed., 
1986. 
to contain and express sequences encoding a MKRN enzyme 
polypeptide. These include, but are not limited to, microor-
ganisms, such as bacteria transformed with recombinant bac- 60 
teriophage, plasmid, or cosmid DNA expression vectors; 
yeast transformed with yeast expression vectors, insect cell 
systems infected with virus expression vectors (e.g., bacu-
lovirus ), plant cell systems transformed with virus expression 
vectors (e.g., cauliflower mosaic virus, CaMV; tobacco 65 
mosaic virus, TMV) or with bacterial expression vectors 
(e.g., Ti or pBR322 plasmids), or animal cell systems. 
5.1 Detecting Expression 
A variety of protocols for detecting and measuring the 
expression of a MKRN polypeptide, using either polyclonal 
or monoclonal antibodies specific for the polypeptide, are 
known in the art. Examples include enzyme-linked immun-
osorbent assay (ELISA), radioimmunoassay (RIA), and fluo-
rescence activated cell sorting (FACS). A two-site, mono-
clonal-based immunoassay using monoclonal antibodies 
reactive to two non-interfering epitopes on a MKRN polypep-
tide can be used, or a competitive binding assay can be 
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employed. These and other assays are described in Hampton 
et al., SEROLOGICAL METHODS: A LABORATORY 
MANUAL, APS Press, St. Paul, Minn., 1990) and Maddox et 
al., J. Exp. Med. 158, 12111216, 1983). 
16 
ential display (Liang & Pardee, Science 257, 967-71, 1992; 
U.S. Pat. No. 5,262,311), andmicroarrays. 
The differential expression information may itself suggest 
relevant methods for the treatment of disorders involving 
5 .2 Expression and Purification of Polypeptides 
Host cells transformed with nucleotide sequences encod-
ing MKRN polypeptide can be cultured under conditions 
suitable for the expression and recovery of the protein from 
cell culture. The polypeptide produced by a transformed cell 
can be secreted or contained intracellularly depending on the 
sequence and/or the vector used. As will be understood by 
those of skill in the art, expression vectors containing poly-
nucleotides which encode MKRN polypeptides can be 
designed to contain signal sequences which direct secretion 
of soluble MKRN polypeptides through a prokaryotic or 
eukaryotic cell membrane or which direct the membrane 
insertion of membrane-bound MKRN polypeptide. 
5 degradation of telomeres. For example, treatment may 
include a modulation of expression of the differentially 
expressed genes and/or the gene encoding the MKRN 
polypeptides. The differential expression information may 
indicate whether the expression or activity of the differen-
10 tially expressed gene or gene product or the MKRN gene or 
gene product are up-regulated or down-regulated. 
Further, use of anti-MKRN antibodies can be used to 
screen for tumors possessing varying expression of MKRN 
polypeptides. As the characterization of tumors possessing 
6. Antibodies 
15 MKRN expression is elucidated, this information will be 
useful in determining metastatic potential of a given tumor, 
which in turn will assist in determining an appropriate treat-
ment regime. Also, related to the foregoing, as drugs are 
developed and identified that affect MKRN activity and/or Antibodies are referenced herein and various aspects of the 
subject invention utilize antibodies specific to MKRN 
polypeptide(s ). As described above, one example of an thera-
peutic agent may pertain to an antibody. Any type of antibody 
known in the art can be generated to bind specifically to an 
epitope of an MKRN polypeptide. "Antibody" as used herein 
includes intact immunoglobulin molecules, as well as frag- 25 
ments thereof, such as Fab, F(ab')2 , andFv, which are capable 
20 expression, screening of tumors will facilitate selection of 
appropriate anti-cancer agents. Accordingly, another 
embodiment of the invention pertains to a method of screen-
ing of a tumor cell for MKRN expression. 
of binding an epitope of an MKRN polypeptide. Typically, at 
least 6, 8, 10, or 12 contiguous amino acids are required to 
form an epitope. However, epitopes which involve non-con-
tiguous amino acids may require more, e.g., at least 15, 25, or 30 
50 amino acids. 
An antibody which specifically binds to an epitope of an 
MKRN polypeptide can be used therapeutically, as men-
tioned, as well as in immunochemical assays, such as Western 
blots, ELISAs, radioimmunoassays, immunohistochemical 35 
assays, immunoprecipitations, or other immunochemical 
assays known in the art. Various immunoassays can be used to 
identify antibodies having the desired specificity. Numerous 
protocols for competitive binding or immunoradiometric 
assays are well known in the art. Such immunoassays typi- 40 
cally involve the measurement of complex formation 
between an immunogen and an antibody which specifically 
binds to the immunogen. Antibodies useful for embodiments 
Example 1 
Cell Lines and Culture Conditions 
The human lung carcinoma cell line H1299 was cultured in 
RPMI-1640 medium, and the human fibrosarcoma cell line 
HT1080 was cultured in Dulbecco's modified Eagle's 
medium supplemented with 10% fetal bovine serum, 100 
units/ml penicillin, and 100 µg/ml streptomycin in 5% co2 at 
37° C. The human osteosarcoma cell line Saos-2 was main-
tained in McCoy's SA medium containing 15% fetal bovine 
serum, 100 units/ml penicillin, and 100 µg/ml streptomycin. 
To establish cell lines stably expressing MKRNl, the 
MKRN1-V5 construct was transfected into HT1080 cells 
using Lipofectamine Plus (Invitrogen, Carlsbad, Calif.) 
according to the manufacturer's instructions. As a control, 
HT1080 cells were also stably transfected with an empty 
vector. Multiple independent single clones were isolated and 
checked for protein expression by immunoblotting with anti-
V5 antibody. of the subject invention may be polyclonal, but are preferably 
monoclonal antibodies. 45 Expression Vectors 
7. Identification of Differentially Expressed Genes and Pro-
filing of Cancers 
The Flag-hTERT expression vector was constructed by 
cloning the full-length hTERT cDNA into pCMV-Tag2 vec-
tor (Stratagene). The hTERT-HA expression vector (gener-
ously provided by H. Seimiya, Japanese Foundation for Can-
cer Research) has been described (Seimiya et al. 2000). The 
MKRNl expression vector was constructed by inserting the 
EcoRI and Natl fragment from the full-length MKRNl 
cDNA (generated by PCR with the appropriate synthetic 
primers) into pcDNA3.1 (Invitrogen, Carlsbad, Calif.). The 
expression vector for GST-hTERT-HA was constructed by 
cloning the fragment encoding the C-terminal region (amino 
acid 946-1132) ofhTERT into pGEX-5X-2 (Amersham Bio-
sciences Inc., Piscataway, N.J.). MKRNl and MKRNl 
mutants were subcloned into pGEX-6P-1 for expression in 
To identify differentially expressed genes total RNA or, 
preferably, mRNA is isolated from tissues of interest. For 
example, RNA samples are obtained from tissues of experi- 50 
mental subjects and from corresponding tissues of control 
subjects. Any RNA isolation technique that does not select 
against the isolation of mRNA may be utilized for the purifi-
cation of such RNA samples. See, for example, Ausubel et al., 
ed., CURRENT PROTOCOLS IN MOLECULAR BIOL- 55 
OGY, John Wiley & Sons, Inc. New York, 1987-1993. Large 
numbers of tissue samples may readily be processed using 
techniques well known to those of skill in the art, such as, for 
example, the single-step RNA isolation process of Chomc-
zynski, U.S. Pat. No. 4,843,155. 
Transcripts within the collected RNA samples that repre-
sent RNA produced by differentially expressed genes are 
identified by methods well known to those of skill in the art. 
They include, for example, differential screening (Tedder et 
al., Proc. Natl. Acad. Sci. U.S.A. 85, 208-12, 1988), subtrac- 65 
tive hybridization (Hedrick et al., Nature 308, 149-53; Lee et 
al., Proc. Natl. Acad. Sci. U.S.A. 88, 2825, 1984), and differ-
60 bacteria. The GST fusion proteins were expressed, purified, 
and cleaved with PreScission™ protease to remove the 
cleaved GST according to the manufacturer's instructions 
(Amersham Biosciences Inc., Piscataway, N.J.). 
Yeast Two-Hybrid Screening 
Yeast two-hybrid screening was performed as described 
(Lee et al. 2004). Briefly, the yeast strain EGY48 harboring 
pLexA-hTERT (amino acid 946-1132) and pSH18-34 was 
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transformed by the lithium acetate method with a HeLa 
cDNA library fused to the activation domain vector pB42AD 
(Clontech). 
Immunoprecipitation and Immunoblotting 
H1299 cells were transiently transfected with the expres- 5 
sion vectors indicated in the figure legends using TransFast 
transfection reagent (Promega, Madison, Wis.) according to 
the manufacturer's instructions. Cells were lysed with buffer 
containing 0.5% NP-40, 50 mM Tris-HCl (pH 7 .5), 150 mM 
NaCl, 2 mM phenyl methylsulphonyl fluoride. After centrifu- 10 
gation at 12,000 rpm for 30 min, the supernatants were immu-
noprecipitated for 2 hours with anti-Flag (Sigma, St. Louis, 
Mo.) or anti-HA (Santa Cruz biotechnology, Santa Cruz, 
Calif.) antibodies and then incubated with Sepharose beads 
conjugated to Protein G (Amersham Biosciences Inc., Piscat- 15 
away, N.J.). When ubiquitin conjugates of hTERT were 
detected, immunoprecipitation was performed with lysis 
buffer containing 0.1 % SDS to dissociate its interacting pro-
teins. Immunoblot analyses were performed using anti-
hTERT (Santa Cruz biotechnology, Santa Cruz, Calif.), anti- 20 
V5 (Invitrogen, Carlsbad, Calif.), anti-HA, and anti-Flag 
antibodies. 
In Vitro Ubiquitination Assay 
GST-hTERT-HA expressed in bacteria was used as sub-
strate for in vitro ubiquitination assay (Park et al. 2004). The 25 
ubiquitination reactions were carried out in buffer (50 mM 
Tris-HCl, pH 7.5, 2 mMATP, 2.5 mM MgC12 , 5 mM dithio-
threitol, and 0.05% NP-40) containing yeast El (0.05 µg), E2 
(0.2 µg), and Hiscubiquitin (0.8 µg) (6xHis disclosed as SEQ 
ID NO: 7) in a final volume of 30 µ!. Purified wild-type or 30 
mutant MKRNl as an E3 enzyme was added as indicated in 
the figure legend. The reaction mixtures were incubated at 
30° C. for 60 min and terminated with sample loading buffer 
and run on SDS-PAGE. Slow migrating ubiquitin conjugates 
were visualized by immunoblot analysis with anti-HA anti- 35 
body. 
Telomerase Assays 
The telomeric repeat amplification protocol (TRAP) was 
used as previously described (Kim et al. 2003). Cell extracts 
(200 ng of protein) were added to telomerase extension reac- 40 
tions and incubated for 20 min at 37° C. Reactions were 
stopped by heating at 94 ° C. for 90 seconds and placed on ice. 
PCR was performed using the TS primer and ACX primer for 
30 cycles ( denaturation at 94 ° C. for 30 s, annealing at 60° C. 
for 30 s, and extension at 72° C. for 30 s). As an internal 45 
telomerase assay standard (ITAS), NT and TSNT primers 
were added to the PCR mixture as previously described (Kim 
and Wu 1997). Telomerase products were resolved by elec-
trophoresis on a 12% nondenaturing polyacrylamide gel. 
Bands were then visualized by staining with SYBR Green 50 
(Molecular Probes, Eugene, Oreg.). The signal intensity was 
quantified with a LAS-1000 Plus Image analyzer (Fuji Photo 
Film, Tokyo, Japan). 
Terminal Restriction Fragment (TRF) Analysis 
To measure the telomere length, genomic DNA was 55 
digested with RsaI and Hinfl and separated on 0.7% agarose 
gel. DNA samples were transferred to a nylon membrane 
(Hybond N+, Amersham Biosciences Inc., Piscataway, N.J.) 
and hybridized with a 32P labeled probe (TTAGGG)20 (SEQ 
ID NO: 6). Signals were detected by phosphoimage analyzer 60 
(Fuji Photo Film, Tokyo, Japan). 
hTERT is Sensitive to the Hsp90 Antagonist Geldanamycin 
Inhibition ofHsp90 function by GA prevents the assembly 
of active telomerase (Holt et al. 1999). Because GA mediates 
the dissociation of Hsp90 from its client proteins and pro- 65 
motes rapid degradation by the proteasome (Goetz et al. 
2003), the inventors believed that hTERT would be sensitive 
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to the Hsp90 antagonist. To investigate this possibility, the 
inventors transfected H1299 cells with Flag-tagged hTERT 
and assessed protein levels in the absence or presence of GA. 
hTERT protein was highly expressed in untreated cells but 
was down-regulated in a time-dependent manner in response 
to GA treatment, with over 50% of the protein being elimi-
nated within 2 hours of treatment (FIG. IA, lanes 1-5). TRFl 
expression levels were not affected by GA treatment (FIG. 
IA, middle blot). GA also decreased the level of hTERT 
expression in a dose-dependent manner (FIG. IB). To verify 
the ability of GA to down-regulate endogenous hTERT lev-
els, H1299 cells were treated with GA and immunoblotted 
using a polyclonal anti-hTERT antibody. Treatment of cells 
with GA significantly decreased endogenous hTERT levels 
(FIG. IC, upper blot). 
The Hsp90 chaperone complex binds to hTERT and influ-
ences proper assembly with hTR to form an active enzyme 
(Holt et al. 1999; Forsythe et al. 2001). The inventors tested 
the influence of GA-induced degradation ofh TERT on telom-
erase activity in H1299 cells. Incubation with GA reduced 
telomerase activity in a time-dependent manner (FIG. ID). To 
more clearly determine the effects of GA on telomerase activ-
ity, N-terminal Flag-tagged hTERT and C-terminal 
HA-tagged hTERT constructs were transfected to Saos-2 
cells that lack detectable telomerase activity (Kim et al. 
2003 ). The forced expression of exogenous hTERT produced 
telomerase activity in these cells (FIG. IE). Furthermore, 
incubation with GA reduced telomerase activity to near basal 
levels. These results suggest that Hsp90 is not only important 
for the proper conformation ofhTERT but also for maintain-
ing telomerase assembly. 
hTERT is Ubiquitinated and Degraded Via the Proteasomal 
Pathway 
Reduction in hTERT levels could be due to degradation 
and/or turnover of the protein. To examine whether the GA-
mediated degradation of hTERT proceeds via the protea-
some, the inventors pretreated H1299 cells for 2 hours with 
the specific proteasome inhibitor, MG132, and subsequently 
incubated with GA for 4 hours. Incubation of cells with 
MG132 rescued the GA-induced down-regulation ofhTERT 
(FIG. IA, lane 6 in upper blot) whereas pretreatment of cells 
with the lysosomal proteolysis inhibitor E-64 had no effect on 
hTERT levels (compare lanes 6 and 7). In the absence of GA 
treatment, incubation of cells with either MG132 or E-64 
alone did not cause a significant change in the levels of 
hTERT expression relative to untreated controls (FIG. IA, 
lanes 8 and 9 in upper blot). These results indicate that GA-
induced down-regulation of hTERT is due to degradation 
mediated by the proteasome pathway. The inventors also 
demonstrate that endogenous hTERT levels are affected by 
the proteasome pathway. Pretreatment of cells with MG 132 
before treatment with GA rescued the proteasomal degrada-
tion of the endogenous hTERT protein (FIG. IC, lower blot). 
GA-mediated protein degradation by the proteasome 
depends on conjugation ofubiquitin to the Hsp90 client pro-
tein (Isaacs et al. 2002; Citri et al. 2002). To determine 
whether hTERT is ubiquitinated in vivo prior to its degrada-
tion, H1299 cells co-transfected with Flag-tagged hTERT 
and HA-tagged ubiquitin constructs were treated with GA, 
ALLnN (a general proteasome inhibitor) or both. The immu-
noprecipitated products were evaluated by immunoblotting 
with selected probes as described in FIG. 2. Treatment of GA 
alone decreased hTERT levels; however, GA plus ALLnN 
reversed this trend (FIG. 2A, compare lanes 3 and 4 in upper 
blot). Treatment with ALLnN alone did not affect hTERT 
levels relative to controls (FIG. 2A, compare lanes 1 and 2 in 
upper blot). Note that the amount of high molecular weight 
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smearing was more noticeable in the ALLnN-treated cells 
(FIG. 2A, compare lanes 1 and 3 with lanes 2 and 4 in upper 
blot). To confirm that these slower migrating bands repre-
sented ubiquitinated hTERT, anti-Flag immunoprecipitates 
were probed with anti-HA antibody, which will illuminate 5 
ubiquitin-modified hTERT (FIG. 2A, lower blot). Again, 
ubiquitinated hTERT was dramatically elevated in the pres-
ence of the proteasome inhibitor ALLnN (FIG. 2A, compare 
lanes 1 and 3 with lanes 2 and 4 in lower blot). These high 
molecular smears are diagnostic for polyubiquitinated pro- 10 
teins (Gimta et al. 2003). This modification was substantially 
enhanced by the treating cells with both ALLnN and GA 
(FIG. 2A, compare lanes 2 and 4 in lower blot). In addition, 
hTERT displayed enhanced GA-induced ubiquitination in a 
dose-dependent manner in thepresenceofMG132 (FIG. 2B). 15 
These data indicate that hTERT is ubiquitinated in 
GA-treated cells prior to proteasome-dependent degradation 
in a manner similar to other Hsp90 client proteins (Isaacs et al. 
2002; Citri et al. 2002). Without being bound to any particular 
theory, it is the inventors belief that two counteracting pro- 20 
cesses mediate hTERT levels: proteasomal degradation by 
the ubiquitination pathway and rescue (or protection) from 
degradation by Hsp90. The dynamic balance between these 
two processes determines equilibrium levels of hTERT, 
which then sets cellular telomerase activity. It is also worth 25 
noting that polyubiquitinated hTERT forms were signifi-
cantly elevated by ALLnN even in the absence of GA treat-
ment (FIG. 2C, lanes S and 6). These results suggest that 
hTERT is subject to ubiquitination even in the absence of GA. 
Identification of a RING Finger Protein that Interacts with 30 
hTERT 
20 
revealed that hTERT co-immunoprecipitated with MKRNl 
in cells treated with ALLnN but not in negative drug control 
cells (FIG. 3C, compare lanes 7 and 8), suggesting that 
hTERT binds to MKRNl in mammalian cells. When this 
experiment was modified using N-terminal Flag-tagged 
hTERT and MKRNl-VS expression vectors with a different 
proteasome inhibitor (MG132), essentially identical results 
were obtained (FIG. 3D). 
MKRNl is an E3 Ubiquitin-Ligase that Enhances Ubiquiti-
nation ofhTERT 
We next investigated the involvement ofMKRNl in ubiq-
uitination ofhTERT. In vitro ubiquitination assays using puri-
fied components showed that the C-terminal domain (resi-
dues 946-1132) of hTERT was efficiently ubiquitinated by 
wild-type MKRNl, but not by mutants MKRNlH3 o7E or 
MKRNl Ll.c (FIG. 4A). Thus, while MKRNl is an E3 ligase 
for hTERT, mutating the RING finger domain destroys this 
activity in vitro, indicating that the RING finger domain is 
indispensable for E3 activity. 
To investigate whether MKRNl contributes to the ubiquiti-
nation ofhTERT in vivo, Hl 299 cells were cotransfected with 
Flag-hTERT, HA-ubiquitin, and MKRNl-VS constructs, and 
immunoprecipitated with anti-Flag antibody followed by 
immunoblotting with anti-HA antibody. Ubiquitin conju-
gates of hTERT were easily detected in the presence of 
MG132 (FIG. 4B, lane 2 in upper blot). The amount ofubiq-
uitinated hTERT was significantly reduced in cells cotrans-
fected with MKRNl plus MKRNl H 3o7E (lane 6) compared to 
cells transfected with MKRNl alone (lane 2) or in cells 
cotransfected with MKRNl plus MKRNlLl.c (lane 4). These 
data demonstrate that mutating the RING finger in 
MKRNlH3 o7E does not impair its ability to interact with 
hTERT but disrupts the domain structure of the ubiquitin 
ligase activity, thereby yielding a dominant negative pheno-
Ubiquitination is carried out by a cascade of reactions 
catalyzed by ubiquitin-activating enzyme (El), ubiquitin-
conjugating enzyme (E2), and ubiquitin ligase (E3) (Hershko 
et al. 1998; Pickart et al. 2001 ). E3 proteins are known to play 
a pivotal role in determining the specificity of the system by 
recognizing target substrates. The inventors established a 
yeast two-hybrid system to search for an E3 ligase involved in 
hTERT degradation. With the C-terminal domain ofhTERT 
as bait (residues 946-1132), the inventors identified proteins 
that interact with hTERT (FIG. 3A). One of the isolated 
clones contains a C3HC4 -type RING finger domain that is 
present in many E3 ubiquitin ligases (Joazeiro et al. 1999; 
Levkowitz et al. 1999; Lorick et al. 1999). It was discovered 
that the protein was identical to the Makorin ring finger pro-
tein 1 (MKRNl) (Gray et al. 2000). MKRNl is uniformly 
expressed in all tissues and encodes a putative ribonucleopro-
tein with a distinctive array of zinc-finger motifs, including 
four C3H zinc-finger motifs, an unusual Cys-His motif, and a 
highly conserved RING finger domain (FIG. 3B). MKRNl 
orthologs have been identified in a wide spectrum of species 
(from invertebrates to vertebrates), suggesting an ancient ori-
gin of this highly conserved gene (Gray et al. 2000). 
35 type. When the levels of ectopically expressed MKRNl and 
mutants were examined, MKRNl expression was clearly 
elevated by MG132 treatment (FIG. 4B, compare lanes 1 and 
2 in lower blot). In contrast, MG132 had no effect on the 
amount of MKRNl Ll.c (compare lanes 3 and 4), suggesting 
The physical interaction between MKRNl and hTERTwas 
examined by co-immunoprecipitation experiments in cells 
cotransfected with C-terminal HA-tagged hTERT and 
MKRNl-VS expression vectors (FIG. 3C). The data show 
that MKRNl was barely detectable in lysates directly probed 
with anti-VS antibody (FIG. 3C, lanes 1 and3). This suggests 
that MKRNl may be rapidly degraded through auto-ubiquiti-
nation like other ring finger proteins that promote their own 
ubiquitination/degradation (Joazeiro and Weissman 2000). In 
the presence of ALLnN, however, there was a significant 
increase in both unmodified and ubiquitinated MKRNl spe-
cies (FIG. 3C, lanes 2 and 4). Immunoprecipitation of cell 
lysates with anti-HA antibody (hTERT) and subsequent 
immunoblot analysis with anti-VS antibody (MKRNl) 
40 that the deleted C-terminal region is required for auto-ubiq-
mtmation of MKRNl. When both MKRNl and 
MKRNlH3 o7E were cotransfected, we were able to detect 
MKRNl H 3o7 E in the absence of MG 132 although the expres-
sion level was slightly less (-2-fold) compared with that 
45 elicited by the MG132 treatment (compare lanes S and 6). 
Thus, mutating the histidine residue in the RING finger motif 
inhibits auto-ubiquitination. 
To examine the in vivo role ofMKRNl in ubiquitination of 
hTERT, the inventors cotransfected H1299 cells with Flag-
50 hTERT plus HA-ubiquitin and immunoprecipitated with anti-
Flag antibody followed by immunoblotting with anti-HA 
antibody. Although no hTERT-ubiquitin conjugates were 
observed in untreated cells in this short exposed blot (FIG. 
4C, lane 1 in upper blot), low levels were detected after 4S-60 
55 minutes of MG132 treatment (lanes S and 6). In marked 
contrast, co-expression of MKRNl caused a dramatic 
increase in the amount of ubiquitinated hTERT species (lanes 
7-12). When the expression levels ofMKRNl were examined 
by immunoblotting with anti-VS antibody, both unmodified 
60 and polyubiquitinated MKRNl species increased in a time-
dependent manner in response to MG 13 2 treatment (FIG. 4C, 
lanes 7-12 in lower blot). On the basis of these data, the 
inventors conclude that MKRNl is an E3 ligase for hTERT 
ubiquitination in manmialian cells. Although our findings 
65 show that MKRNl associates with and efficiently ubiquiti-
nates hTERT, the foregoing data does not exclude the possi-
bility of other E3 ligases for hTERT. The Hsp90/Hsp70-
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associated U-box ubiquitin ligase CHIP (carboxy terminus 
Hsc70-interacting protein) may mediate the GA-stimulated 
degradation of some Hsp90 client proteins (Connell et al. 
2001; Meacham et al. 2001 ). Whether CHIP E3 activity regu-
lates in vivo stability ofhTERT remains to be elucidated. 
Overexpression of MKRNl Decreased Telomerase Activity 
and Telomere Length. 
Because MKRNl functions as an E3 ligase for hTERT 
ubiquitination in vivo, the inventors examined whether 
ectopic expression of MKRNl affects telomerase activity. 10 
The inventors established HT! 080 cell lines stably express-
ing MKRNl (or an empty vector negative control). Levels of 
ectopically expressed MKRNl were examined by immuno-
blotting with anti-VS antibody (FIG. SA). Treatment of 
15 
MG132 resulted in a substantial increase in MKRNl com-
pared to untreated cells (compare lanes 3 and 6). Cells 
expressing MKRNl and the empty vector grew normally and 
exhibited no detectable differences in growth rates or mor-
phology over 45 population doublings (PD). After 45 PD, the 20 
inventors compared telomerase activity in stable cell lines 
expressing MKRNl and the empty vector. Telomerase activ-
22 
Example 2 
Identification ofhMKRNl Interactive Factors by 
Yeast Two-Hybrid Screening 
Yeast two-hybrid screens similar to that described in 
Example 1 are implemented, except instead of screening with 
pLexA-hTERT, pLexA-MKRNl with the same HeLa cDNA 
library fused to the activation domain vector pB42AD 
(Clonetech) is used. This will allow identification additional 
protein partners for MKRNl E3 ubiquitin ligase. 
Prior to setting up the system with MKRN as bait, autoac-
tivation MKRNl in yeast is checked, since it must be verified 
that DNA binding fusions with MKRN do not activate tran-
scription alone. To ensure that the MKRNl-DNA binding 
fusion proteins are behaving correctly ( eg., properly folded), 
a known positive couple (hTERT as prey and MKRNl as bait) 
is verified. The inventors showed that hTERT946- 1132 gave a 
strong positive Lacz signal with WT hMKRNl prey; there-
fore, reversing the partners will give concordant results if the 
MKRNl is a functional partner. In fact, for any subsequent 
positives obtained by 2-hybrid screening described below, we 
will perform a reciprocal swap like this to ensure concor-
dance. Note also that screening with libraries selects for opti-
mized interactions. It is known, for example that subdomains 
may interact better than whole proteins (probably reflects 
domain folding, stearic access and so forth). For this reason, 
our original screening using hTERT as bait (FIG. 3) was 
successful with a domain spanning residues 946-1132 of 
30 hTERT. It is reasonable to propose a similar approach using 
MKRNl as bait. The 482 amino acid hMKRNl are divided 
ity in cells expressing MKRNl was decreased by -5-fold 
relative to the control cell line (FIG. SB). The overexpression 
ofMKRNl resulted in a down-regulation of the endogenous 25 
hTERTprotein(FIG. SC). These results suggestthatMKRNl 
acts as a negative regulator oftelomerase. However, it is not 
clear whether this decrease is due to a MKRNl-related 
decrease in the expression of hTERT or hTR genes. To 
address this possibility, the impact of MKRNl on gene 
expression ofhTERT and hTR was evaluated using RT-PCR 
analysis (Kim et al. 2002). Whereas MKRNl mRNA level 
was -5-fold higher in cells expressing the gene (relative to 
control cells), we observed no significant differences in 
35 
steady-state levels ofhTERT mRNA or hTR transcripts in cell 
lines expressing MKRNl and the empty vector (FIG. SD). To 
examine whether MKRNl-mediated decrease in telomerase 
activity was attended by changes in telomere lengths, we 
performed a terminal restriction fragment (TRF) size analysis 
(Lee et al. 2004). Control cells exhibited an average telomere 
length of -6 kb with most fragments spread over a range of 
approximately 5 to 7 kb (FIG. SE). Telomeres were clearly 
shortened in the clones expressing MKRNl with a decrease in 
TRF length to -4 kb and spanning down to roughly 2.5 kb. 
These findings suggest that MKRNl exerts a negative role in 
telomere length maintenance and/or regulation. 
into subclone domains in the pLexA-MKRNl bait. Positive 
and negative controls (hTERT and TRFl respectively) are 
used. As shown in xx FIG. 12, we will prepare a series of 
intact as well as overlapping and non-overlapping clones. The 
domain organization of hMKRNl is useful in selecting the 
appropriate clones. For example, domain analysis by "NCBI 
Conserved Domain Search" algorithm reveals that 
hMKRNl 132- 240 contains a strong homology to RecQ heli-
40 case. Given the conservation ofMKRNl (Reprint #1 ), it may 
have other activities and targets that are unrelated to the 
ubiquitin-proteasome pathway. Moreover, the RecQ domain 
should not be affected by a single residue change in the RING 
finger at H307; thus the hMKRNlH3 0 7E mutant should be 
45 able to bind these targets in the absence ofE3 ubiquitin ligase 
function. All of these constructs may be subcloned, 
sequenced and checked for their ability to couple with 
hTERT946- 1132 using the 2-hybrid assay. These data enable 
sorting out other positives since the regions of binding 
The data presented herein demonstrates that MKRNl 
markedly enhances hTERT ubiquitination in the absence of 
GA treatment. This suggests that MKRNl functions as an E3 
ligase for the constitutive ubiquitination of mature hTERT 
assembled with hTR in the nucleus when the molecular chap-
erone Hsp90 is intact. Additionally, MKRNl may perform 
this same function with newly synthesized hTERT in cyto-
55 
plasm. Ubiquitination of hTERT may be regulated by 
changes in the expression and activity of MKRNl and de-
ubiquitinating enzymes. Moreover, continued expression of 
MKRNl in telomerase-positive cells resulted in a decrease in 
telomerase activity and cells with shortened telomeres. Thus, 
MKRNl regulates telomerase activity and telomere length 
through dynamic control of hTERT protein stability. The 
function oftelomerase during development, aging, and can-
cer has been extensively studied (Kim et al. 2002). MKRNl, 
50 betweenhTERT/MKRN are established; thus, any new genes 
found to interact with non-hTERT binding sites signify a 
novel partner proteins (for example binding partners in RecQ 
helicase). 
Characterization of Specificity 
Positives are characterized similar to the strategies 
described in Example 1. Depending on the number of posi-
tives, different approaches are taken. For example, a limited 
number of positives are obtained involving only a few of our 
bait constructs, a new transformation with positive and nega-
60 tive controls (including empty vectors) is repeated and re-
assayed for specificity, bait swaps and then sequenced. If a 
larger number of positives (50-100) are obtained, direct 
sequence analysis is conducted. Blast search characteriza-
tions for known proteins, conserved domains and homology 
a post-translational modifier ofhTERT, may play an impor-
tant role in telomere length maintenance and/or regulation 
through ubiquitin-mediated proteolysis ofhTERT. 
65 with existing genes and gene products, are conducted see 
Example 1. Sequence data may be analyzed. For example, 
genes not in frame with the activation domain, indications of 
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gene inversions (polyAAA tail position), genes encoding 
RNA or retroposons would be less interesting. 
Positive interactions is also confirmed outside the yeast 
system. In brief, pull downs and Co-IP experiments in a 
model cell system (such as HeLa cells which express low 
levels ofMKRNl and HEK293 cells expressing high levels of 
MKRNl) are performed. Co-localization using immunofluo-
rescence and confocal microscopy to validate the 2-hybrid 
couple in mammalian cells may also be performed. 
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SEQUENCE LISTING 
<160> NUMBER OF SEQ ID NOS, 7 
<210> SEQ ID NO 1 
<211> LENGTH, 3025 
<212> TYPE, DNA 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 1 
gaacgggtgc ctcagtgtcc ttcccctccc ctcgcctggc ctcgcgtcct ctccccgcag 60 
ccggaccgga actatgtgat cccggaagtt ccgggccttt gctgtgtggg ataaacagta 120 
atggcggagg ctgcaactcc cggaacaaca gccacaacat caggagcagg agcggcagcg 180 
gcgacggcgg cagcagcctc ccccaccccg atccccacag tcaccgcccc gtccctgggg 240 
gcgggcggag ggggcggcgg cagcgacggc agcggcggcg gctggactaa acaggtcacc 300 
tgcaggtatt ttatgcatgg ggtttgtaag gaaggagaca actgtcgcta ctcgcatgac 360 
ctctctgaca gtccgtatag tgtagtgtgc aagtattttc agcgagggta ctgtatttat 420 
ggagaccgct gcagatatga acatagcaaa ccattgaaac aggaagaagc aactgctaca 480 
gagctaacta caaagtcatc ccttgctgct tcctcaagtc tctcatcgat agttggacca 540 
cttgttgaaa tgaatacagg cgaagctgag tcaagaaatt caaactttgc aactgtagga 600 
gcaggttcag aggactgggt gaatgctatt gagtttgttc ctgggcaacc ctactgtggc 660 
cgtactgcgc cttcctgcac tgaagcaccc ctgcagggct cagtgaccaa ggaagaatca 720 
gagaaagagc aaaccgccgt ggagacaaag aagcagctgt gcccctatgc tgcagtggga 780 
gagtgccgat acggggagaa ctgtgtgtat ctccacggag attcttgtga catgtgtggg 840 
ctgcagctcc tgcatccaat ggatgctgcc cagagatcgc agcatatcaa atcgtgcatt 900 
gaggcccatg agaaggacat ggagctctca tttgccgtgc agcgcagcaa ggacatggtg 960 
tgtgggatct gcatggaggt ggtctatgag aaagccaacc ccagtgagcg ccgcttcggg 1020 
atcctctcca actgcaacca cacctactgt ctcaagtgca ttcgcaagtg gaggagtgct 1080 
aagcaatttg agagcaagat cataaagtcc tgcccagaat gccggatcac atctaacttt 1140 
gtcattccaa gtgagtactg ggtggaggag aaagaagaga agcagaaact cattctgaaa 1200 
tacaaggagg caatgagcaa caaggcgtgc aggtattttg atgaaggacg tgggagctgc 1260 
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-continued 
ccatttggag ggaactgttt ttacaagcat gcgtaccctg atgccggtag agaggagcca 
cagagacaga aagtgggaac atcaagcaga taccgggccc aacgaaggaa ccacttctgg 
gaactcattg aggaaagaga gaacagcaac ccctttgaca acgatgaaga agaggttgtc 
acctttgagc tgggcgagat gttgcttatg cttttggctg caggtgggga cgacgaacta 
acagactctg aagatgagtg ggacttgttt catgatgagc tggaagattt ttatgacttg 
gatctatagc aaccttgcgt ggcgtgtgaa ctggtctgct gacctcagac agcagctgtc 
ccctgtggtg gtgtggcagt cctgttgttc tctcctaggc aggcctctca actccaggtg 
ctgtcctaag aatttttacc cagggcctgt cttctcaacc cctcaccttt ccctgaggag 
tgtgttgttt tccctgttga aaaaagttac aaaaataaat cttaaagtta gttttttgta 
acacgaattt aactgtcaga cagttagtgt aagtgtgttg cgtcatctgt tttcaaccag 
attgcattta tggacttttc acacactcat tttgaggacc ccaggttcaa aagtaaaagc 
actggccctg ctttggggtc caagaatagg agtgatgggt gaagggacct aacctggcca 
atagccctct gccccacaca tgggatgtgg atccttgacg tttctggtga aatctgcaca 
tctgtgtttt tatatctgtt ccctaccctg taatccctac cacgtgcact tgttctgtgg 
ttttggtctc ttgtttaatt gcacacaagt aatactactg ggtaaccaga atcaggtgtg 
aatgtgttga gattttttac tgttttgcat gataggaaaa ttgaaaaaga atacgtataa 
aagatagaga ggcataacat caatgcagag ttggaagttg gctcccaagg gctgacatgg 
tgtgagtgtg tgggtgtgtg ataagcttct catccctgca tagatgcagt attcttagcc 
ttagtagaaa aacctggttt agtggtttaa gccttgtgtg gcaaatagat cttaaagggc 
aaagcagtat attggtagtt gtcaatatag cagtgctagc tctgtctata taaatagaga 
aatggggtta gccatagagg ttaaaactac ctggttatcc catataataa cacaaactgg 
gtcttggata cacagttgta tttaatgttt tacgatctac cctttccagt acaggcactt 
tctgagaaac ctttgtcctc acttgaggca ttttgttgtc gggtttttgt gtttgttttt 
gtgggtattt gcctcattcc acccctgagc tttcaggtag acagacgtga ttcaaaactc 
tgttctaagg tgtttattgt agtggagtaa tgggtttgca gtgataagtc atacttttcc 
accgaaaggg agggcttggg aatccctgag attagctaaa gttaagttgt tggagaattc 
cttgattgga aattgtacct ttgtgttttg ttgctctgtt tcctgaaaat aactcgggga 
tgctcctggt ttgtccatct actgctttga ttccttggat cccacccatt ctttcacttt 
aagaaaaaac aaataattgt tgcagaggtc tctgtatttt gcagctgccc ttttgtaaga 
agcacttttc ccaaataaaa caatt 
<210> SEQ ID NO 2 
<211> LENGTH, 482 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 2 
Met Ala Glu Ala Ala Thr Pro Gly Thr Thr Ala Thr Thr Ser Gly Ala 
1 5 10 15 
Gly Ala Ala Ala Ala Thr Ala Ala Ala Ala Ser Pro Thr Pro Ile Pro 
20 25 30 
Thr Val Thr Ala Pro Ser Leu Gly Ala Gly Gly Gly Gly Gly Gly Ser 
35 40 45 
Asp Gly Ser Gly Gly Gly Trp Thr Lys Gln Val Thr Cys Arg Tyr Phe 
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-continued 
Met His Gly Val Cys Lys Glu Gly Asp Asn Cys Arg Tyr Ser His Asp 
65 70 75 80 
Leu Ser Asp Ser Pro Tyr Ser Val Val Cys Lys Tyr Phe Gln Arg Gly 
85 90 95 
Tyr Cys Ile Tyr Gly Asp Arg Cys Arg Tyr Glu His Ser Lys Pro Leu 
100 105 110 
Lys Gln Glu Glu Ala Thr Ala Thr Glu Leu Thr Thr Lys Ser Ser Leu 
115 120 125 
Ala Ala Ser Ser Ser Leu Ser Ser Ile Val Gly Pro Leu Val Glu Met 
130 135 140 
Asn Thr Gly Glu Ala Glu Ser Arg Asn Ser Asn Phe Ala Thr Val Gly 
145 150 155 160 
Ala Gly Ser Glu Asp Trp Val Asn Ala Ile Glu Phe Val Pro Gly Gln 
165 170 175 
Pro Tyr Cys Gly Arg Thr Ala Pro Ser Cys Thr Glu Ala Pro Leu Gln 
180 185 190 
Gly Ser Val Thr Lys Glu Glu Ser Glu Lys Glu Gln Thr Ala Val Glu 
195 200 205 
Thr Lys Lys Gln Leu Cys Pro Tyr Ala Ala Val Gly Glu Cys Arg Tyr 
210 215 220 
Gly Glu Asn Cys Val Tyr Leu His Gly Asp Ser Cys Asp Met Cys Gly 
225 230 235 240 
Leu Gln Leu Leu His Pro Met Asp Ala Ala Gln Arg Ser Gln His Ile 
245 250 255 
Lys Ser Cys Ile Glu Ala His Glu Lys Asp Met Glu Leu Ser Phe Ala 
260 265 270 
Val Gln Arg Ser Lys Asp Met Val Cys Gly Ile Cys Met Glu Val Val 
275 280 285 
Tyr Glu Lys Ala Asn Pro Ser Glu Arg Arg Phe Gly Ile Leu Ser Asn 
290 295 300 
Cys Asn His Thr Tyr Cys Leu Lys Cys Ile Arg Lys Trp Arg Ser Ala 
305 310 315 320 
Lys Gln Phe Glu Ser Lys Ile Ile Lys Ser Cys Pro Glu Cys Arg Ile 
325 330 335 
Thr Ser Asn Phe Val Ile Pro Ser Glu Tyr Trp Val Glu Glu Lys Glu 
340 345 350 
Glu Lys Gln Lys Leu Ile Leu Lys Tyr Lys Glu Ala Met Ser Asn Lys 
355 360 365 
Ala Cys Arg Tyr Phe Asp Glu Gly Arg Gly Ser Cys Pro Phe Gly Gly 
370 375 380 
Asn Cys Phe Tyr Lys His Ala Tyr Pro Asp Ala Gly Arg Glu Glu Pro 
385 390 395 400 
Gln Arg Gln Lys Val Gly Thr Ser Ser Arg Tyr Arg Ala Gln Arg Arg 
405 410 415 
Asn His Phe Trp Glu Leu Ile Glu Glu Arg Glu Asn Ser Asn Pro Phe 
420 425 430 
Asp Asn Asp Glu Glu Glu Val Val Thr Phe Glu Leu Gly Glu Met Leu 
435 440 445 
Leu Met Leu Leu Ala Ala Gly Gly Asp Asp Glu Leu Thr Asp Ser Glu 
450 455 460 
Asp Glu Trp Asp Leu Phe His Asp Glu Leu Glu Asp Phe Tyr Asp Leu 
465 470 475 480 
Asp Leu 
30 
<210> SEQ ID NO 3 
<211> LENGTH, 54 
<212> TYPE, PRT 
31 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 3 
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-continued 
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu 
1 5 10 15 
Arg Arg Phe Gly Ile Leu Ser Asn Cys Asn His Thr Tyr Cys Leu Lys 
20 25 30 
Cys Ile Arg Lys Trp Arg Ser Ala Lys Gln Phe Glu Ser Lys Ile Ile 
35 40 45 
Lys Ser Cys Pro Glu Cys 
50 
<210> SEQ ID NO 4 
<211> LENGTH, 54 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 4 
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu 
1 5 10 15 
Arg Arg Phe Gly Ile Leu Ser Asn Cys Asn Glu Thr Tyr Cys Leu Lys 
20 25 30 
Cys Ile Arg Lys Trp Arg Ser Ala Lys Gln Phe Glu Ser Lys Ile Ile 
35 40 45 
Lys Ser Cys Pro Glu Cys 
50 
<210> SEQ ID NO 5 
<211> LENGTH, 20 
<212> TYPE, PRT 
<213> ORGANISM, Homo sapiens 
<400> SEQUENCE, 5 
Cys Gly Ile Cys Met Glu Val Val Tyr Glu Lys Ala Asn Pro Ser Glu 
1 5 10 15 
Arg Arg Phe Gly 
20 
<210> SEQ ID NO 6 
<211> LENGTH, 120 
<212> TYPE, DNA 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
probe 
<400> SEQUENCE, 
ttagggttag ggttagggtt agggttaggg ttagggttag ggttagggtt agggttaggg 60 
ttagggttag ggttagggtt agggttaggg ttagggttag ggttagggtt agggttaggg 120 
<210> SEQ ID NO 7 
<211> LENGTH, 
<212> TYPE, PRT 
<213> ORGANISM, Artificial Sequence 
<220> FEATURE, 
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic 
6xHis tag 
32 
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-continued 
<400> SEQUENCE, 7 
His His His His His His 
1 5 
What is claimed is: 
1. A method for isolating and identifying a potential can- 10 
didate for affecting activity oftelomerase in telomerase posi-
tive cancer cells; said method comprising 
(i) applying a yeast-two-hybrid procedure in which a bait 
vector carries a polynucleotide sequence encoding a bait 
MKRN polypeptide, wherein said MKRN polypeptide 15 
comprises SEQ ID NO. 2, and a prey vector carries a 
sequence from a cDNA or genomic DNA library encod-
ing a prey polypeptide; 
(ii) transforming yeast host cells with said first and second 
hybrid vectors; 
(iii) isolating positive transformed cells; 
20 
(iv) extracting second hybrid vector from said positive 
transformed cells to obtain a sequence encoding an 
interacting protein which binds to said MKRN polypep-
tide expressed by said first hybrid vector; and 
(v) identifying a potential candidate for affecting activity 
of telomerase in telomerase positive cancer cells by fur-
ther identifying from the interacting polypeptide 
obtained from step (iv) the polypeptide that modulates 
the expression or activity of said MKRN polypeptide; 
whereby the identified polypeptide that modulates the 
expression or activity of said MKRN polypeptide is the 
potential candidate for affecting activity oftelomerase in 
telomerase positive cancer cells. 
* * * * * 
